Abstract: The invention relates to a method for gaining heat energy from a solar collector, wherein energy is produced through a heat exchanger upon circulating a heat energy absorbent substance in a closed system of the solar collector. According to the invention fluid sulphur is used as heat energy absorbent substance in admixture with 0.5-15% by weight of selenium and/or tellurium, based on the total weight of the heat energy absorbent substance. The invention also relates to heat energy absorbent substances usage in the above method.

Abstract: This invention relates to a primycin-containing colloidal basic gel comprising 5-30% of primycin and 95-70% of N-methyl-pyrrolidone-2. The invention also relates to antibacterial compositions particularly for the treatment of acne vulgaris comprising as active ingredient 0.1-100% of a primycin-containing colloidal basic gel, if desired together with further antimicrobial active ingredients, in admixture with 99.9-0% of usual inert pharmaceutical filling, diluting and other formulating additives. The invention also relates to combination composition comprising as active ingredient 1-60% of a primycin-containing colloidal basic gel and 0.1-40% of further pharmaceutical active ingredient(s), e.g. one or more antibiotic(s), chemotherapeutical agent(s), fungistatic or fungicidal agent(s), steroidal or non-steroidal antiinflammatory agent (s), epithelogenic agent(s), local anaesthetic(s), and/or vitamin(s).

Abstract: The invention relates to a synergistic pharmaceutical composition, which comprises as an active ingredient a combination of 1-phenylalanine and (-)-deprenyl [(-)-N-(1-phenylisopropyl)-N-methyl-N-propinylamine hydrochloride] and optionally carbidopa [3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propionic acid monohydrate] or benzerazide [N-(DL-seryl)-N'-( 2,3,4-trihydroxybenzyl)-hydrazine] in association with conventional inert, non-toxic solid or liquid pharamaceutical carriers. The invention further relates to the preparation of these compositions and to the use thereof for the treatment of depressive symptoms.

Abstract: The invention relates to novel racemic or optically active berban derivatives of the formula (I) ##STR1## wherein R.sup.1 and R.sup.2 represent independently from the other a hydroxyl, straight or branched chain alkoxy group 1 to 6 carbon atoms or R.sup.1 and R.sup.2 together represent a C.sub.1-3 alkylenedioxy group;R.sup.3 and R.sup.4 represent independently from the other hydrogen, straight or branched chain alkyl group, having 1 to 6 carbon atoms and optionally substituted by hydroxyl group, or a C.sub.2-6 alkoxycarbonyl or cyano group; andR.sup.5 represents hydrogen, straight or branched chain alkyl group having 1 to 6 carbon atoms, C.sub.1-7 aliphatic or aromatic acyl group or C.sub.1-7 alkylsulphonyl or arylsulphonyl group, anda salt thereof, to pharmaceutical compositions containing them, to the use as well as to process for preparing the novel compounds. The compounds of the formula (I) are selective .alpha..sub.

Abstract: The invention relates to new oxidiazole-alkyl-purine-derivatives of the Formula I ##STR1## and pharmaceutically acceptable salts thereof wherein A stands for C.sub.1-4 alkylene andR.sup.1 represents C.sub.1-6 alkyl, hydroxyalkyl, halogenoalkyl, carboxyalkyl, C.sub.5-6 cycloalkyl or aminoalkyl of the Formula --(CH.sub.2).sub.n --NR.sup.2 R.sup.3 in which group n is an integer 1-3; R.sup.2 and R.sup.3 each stand for hydrogen or C.sub.1-4 alkyl or together with the adjacent nitrogen atom they are attached to form a 5- or 6-membered nitrogen containing heterocyclic ring which may optionally comprise a further nitrogen atom or an oxygen atom as heteroatom; orR.sup.1 stands for phenyl, hydroxyphenyl, carboxyphenyl, benzyl or dimethoxybenzylThe compounds of the Formula I can be prepared by methods known per se and can be used in therapy as antitussive agents.

Abstract: A new method of treatment is disclosed for a vascular obstructive lesion resulting from restricted blood circulation, characterized by an erythrocyte pathology, in an effected animal subject. The new method involves the administration of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinolinium-theophylli ne-7-acetat e, in a dosage and at a rate sufficient to maintain a blood concentration of at least 0.5 to at most 3 .gamma./ml, calculated on the basis of 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydroisoquinoline.

Abstract: The invention relates to a method of promoting the fat digestion and absorption, which comprises orally administering to an animal subject a partially methylated-.beta.-cyclodextrin optionally together with pharmaceutically acceptable auxiliary and/or additive materials.

Abstract: The invention relates to new 7-oxo-PGI.sub.2 -ephedrine salt analogues of the Formula I ##STR1## wherein A stands for --(CH.sub.2).sub.2 --, cis or trans --CH.dbd.CH-- or --C.tbd.C--;R.sup.1 is lower alkyl or hydrogen;B represents a chemical bond, --CH.sub.2 -- or --CR.sup.2 R.sup.3 ;R.sup.2 stands for lower alkyl or hydrogen;R.sup.3 represents lower alkyl or hydrogen;X is a chemical bond, --O-- or --CH.sub.2 --;R.sup.4 stands for C.sub.1-6 alkyl, C.sub.4-7 cycloalkyl, C.sub.1-6 fluoroalkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, phenyl, substituted phenyl or heteroaryl.The salts of the Formula I show the same pharmacological profile as the sodium salt of PGI.sub.2, they inhibit blood aggregation and the secretion of gastric acid, are useful in the prevention of anginal attacks.